ACADIA Pharmaceuticals (ACAD) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.31
- Estimate
- $0.18
- Surprise
- +69.9%
- Revenue (period 2026-09-30)
- $342.3M
- Score at report (before → after)
- 6.2 → 6.1/10
Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).
How the report landed
ACADIA Pharmaceuticals (ACAD) beat the $0.18 estimate with adjusted EPS of $0.31 — a large 69.9% upside surprise. TrendMatrix's engine moved from Strong Buy (6.2/10) to Buy (Wait) at 6.1/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ACAD Buy (Wait) at 6.1/10.
2 of the last 4 quarters beat the estimate; this quarter's +69.9% surprise compares with a +76.9% four-quarter average. Next scheduled report: 2027-02-24.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: NUPLAZID and DAYBUE
- Concentration risk — Pipeline: remlifanserin RADIANT Phase 2
- Cyclical risk: PE expanding 2.3x (earnings normalizing)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $21.05
- Entry target
- $20.42
- Price target
- $27.47
- Stop
- $19.16
- Upside to target
- +30.5%
- Reward-to-risk
- 2.4:1
Forward estimates sit below the trailing run-rate (23.1× forward vs 10.0× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
ACAD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.64B
- P/E (fwd)
- 23.1
- P/E (ttm)
- 10.0
- 52-week range
- $18.39–$30.96
- Off 52-week high
- 32.0%
- RSI (14)
- 64
- Volume vs avg
- 0.23×
- Score today
- 6.1/10